Country: United Kingdom
Language: English
Source: HMA (Heads of Medicines Agencies)
Equine Rotavirus 40 %
Veterinary Immunogenics Ltd
QI20F
Solution for infusion
BEE
Horses Young
2008-05-28
Revised May 2012 AN: 01006/2011 Page 1 of 6 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT HYPERMUNE-RE Equine Plasma 2. QUALITATIVE AND QUANTITATIVE COMPOSITION QUALITATIVE COMPOSITION Frozen Equine Plasma QUANTITATIVE COMPOSITION ACTIVE SUBSTANCES: Equine Ig G ≥ 24g/l Equine Total Protein ≥ 50g/l Antibodies to Rhodococcus equi ≥ 40% VIL standard EXCIPIENT: Acid Citrate Dextrose-A to ensure citrate content 10 - 20mmols/l For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Plasma for intravenous infusion, after thawing. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Foals from 24 hours to six days of age. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For foals with Failure of Passive Transfer To raise the level of circulating IgG in neonatal foals which have been shown to have low levels (less than 4g/l). The raised level has been demonstrated approximately 24 hours after administration but the duration of the effect is not known. For foals with Normal passive Transfer To raise the level of Rhodococcus equi antibodies. The raised level has been demonstrated approximately 24 hours after administration and raised levels though declining generally last for up to 21 days. 4.3 CONTRAINDICATIONS None Revised May 2012 AN: 01006/2011 Page 2 of 6 4.4 SPECIAL WARNINGSIt is recommended that appropriate Rhodococcus control meas Read the complete document